Business
Co-Marketing Partnership with QIAGEN
Co-Marketing Partnership with QIAGEN.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 2994Q Angle PLC 11 September 2017 \n\n\n\n\n\nFor immediate release\n\n\n 11 September 2017\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nANGLE ANNOUNCES CO-MARKETING PARTNERSHIP WITH QIAGEN \n \nCombines ANGLE's CTC harvesting technology with QIAGEN's downstream analysis and bioinformatics capabilities for circulating tumor cell research \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce it has established a co-marketing agreement with QIAGEN, a world-leading provider of molecular testing solutions with more than 500,000 customers in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). \n \nThe partnership will seek to leverage the advantages of combining ANGLE's world leading Parsortix system for harvesting circulating tumor cells (CTCs) with QIAGEN's liquid biopsy solution portfolio which consists of dedicated NGS (next generation sequencing), PCR (polymerase chain reaction), single cell analysis products and bioinformatics capabilities. The initial focus will be on prostate and breast cancer research applications. \n \nThe agreement entails both companies offering the other's products to its customer base and follows an intensive evaluation of Parsortix by QIAGEN identifying the advantages of the system. \n \nMichael Kazinski, QIAGEN's Senior Director Molecular Preanalytic Technologies commented: \n\"ANGLE's Parsortix system is a unique, epitope-independent CTC solution offering easy, automated processing of whole blood to harvest all types of CTCs, including the clinically relevant mesenchymal CTCs, for analysis. It complements very well with our AdnaTest CTC portfolio, now allowing for both phenotypic and molecular characterization of CTCs. The modular combination abilities of this system with QIAGEN's liquid biopsy-based Sample to Insight offering, including AdnaTest, our targeted RNAseq and single cell solutions, along with our bioinformatics offering, will allow scientists and clinical researchers to significantly advance their research.\"\n \nANGLE Founder and Chief Executive, Andrew Newland, commented: \n\"We are delighted that Par...